Evidence map›Paper›PMID 41817896›Full record

ArticleStem cell reviews and reports2026

UDP-Glucose-P2Y14 Receptor Signaling Enhances the Responsiveness of Hematopoietic Stem/Progenitor Cells to Chemoattractants by Facilitating Membrane Lipid Raft Formation and Nlrp3 Inflammasome Activation.

Mateusz Adamiak, Kannathasan Thetchinamoorthy, Diana Wierzbicka, Michalina Kazek, Emilia Waraksa-Zasada, Agnieszka Lukomska, Katarzyna Brzezniakiewicz-Janus, Janina Ratajczak, Magdalena Kucia, Mariusz Z Ratajczak

Abstract read
In one paragraph

Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mateusz AdamiakCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Kannathasan ThetchinamoorthyCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Diana WierzbickaCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Michalina KazekCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Emilia Waraksa-ZasadaCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Agnieszka LukomskaCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Katarzyna Brzezniakiewicz-JanusDepartment of Hematology, University of Zielona Gora, Multi-Specialist Hospital Gorzow Wlkp, Gorzow Wlkp, Poland.
Janina RatajczakStem Cell Institute at James Graham Brown Cancer Center, University of Louisville, 500 S. Floyd Street, Rm. 107, Louisville, KY, 40202, USA.
Magdalena KuciaCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland.
Mariusz Z RatajczakCenter for Preclinical Studies and Technology, Laboratory of Regenerative Medicine at Medical, University of Warsaw, Warsaw, Poland. mzrata01@louisville.edu.

Funding

Narodowe Centrum Badań i Rozwoju OPUS grant UMO-2021/41/B/NZ3/01589Narodowe Centrum Nauki OPUS grant UMO- 2022/45/B/NZ3/00476 to MKNarodowe Centrum Nauki OPUS grant UMO-2022/45/B/NZ6/00475
6 · The paper itself

Abstract

Purinergic signaling plays an important role in hematopoietic stem/progenitor cell (HSPCs) trafficking, and the role of extracellular alarmin adenosine triphosphate (ATP), a major purinergic signaling mediator, is well established. Another alarmin, uridine diphosphate glucose (UDP-glucose), has also been reported to promote HSPCs trafficking after binding to the P2Y14 purinergic receptor. The molecular basis for this phenomenon, however, remains unclear, especially because UDP-glucose alone does not chemoattract HSPCs. To address this question, we hypothesize that UDP-glucose's role in stem cell trafficking may involve promoting the formation of membrane lipid rafts (MLRs) and enhancing intracellular activation of the Nlrp3 inflammasome, which we have previously identified as essential regulators of HSPCs migration. We found that UDP-glucose promotes HSPCs mobilization not only in response to the pro-mobilizing agent G-CSF but also in response to AMD3100. Furthermore, for the first time, we demonstrate that UDP-glucose also promotes homing and engraftment of HSPCs. We also evaluated the biological effects of a newly synthesized UDP-glucose analog, MRS2690. Our studies included HSPCs in vitro and in vivo trafficking assays, immunostaining and confocal analysis to assess MLRs formation on HSPCs, supported by metabolic analyses to identify metabolites involved in MLRs formation. Our data support our hypothesis that activation of the P2Y14 receptor on HSPCs by its ligands positively modulates cell trafficking, primarily by promoting lipid raft formation and Nlrp3 inflammasome activation. Interestingly, one of the components of MLRs upregulated in response to UDP-glucose is sphinganine, which serves as a fundamental building block and intermediate in the de novo biosynthesis of sphingolipids.

Indexed as

Hematopoietic Stem CellsInflammasomesMembrane MicrodomainsNLR Family, Pyrin Domain-Containing 3 ProteinReceptors, Purinergic P2Receptors, Purinergic P2YSignal TransductionUridine Diphosphate GlucoseAnimalsHumansMiceInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinP2ry14 protein, mouseP2Y14 receptor, humanReceptors, Purinergic P2Receptors, Purinergic P2YUridine Diphosphate GlucoseMembrane lipid raftsNlrp3 inflammasomeStem cell homingStem cell mobilizationUDP-glucose (UDP-G)

Identifiers

PMID41817896
PMCPMC13099678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.